摘要
多药耐药(MDR)describes the resistance of and has been to化疗的肿瘤细胞overexpression ascribed to the of Drug efflux泵。分子影像efflux of Drug泵is helpful to identify the patients who may be to the化疗耐药,因此将avoid the unnecessary and increase the therapeutic治疗的有效性。靶向药物泵efflux成像探针可以非侵入性功能即插即用PGP Evaluate the identification of an important role in and prediction of Response,多药耐药,耐药监测调制。on the other hand,新的抗癌药物的目标,如基于分子表皮生长因子受体(EGFR)和血管生成因子受体可能潜在的chemotherapeutic be combined with the drugs to克服MDR。分子成像目标分子治疗病人visualize response of right and help to select层次清楚,对某些患者有针对性的抗癌疗法。among all the成像的成像方式,包括正电子发射断层核(PET)和单光子发射计算机断层显像(SPECT)“你快速翻译to the Promise for visualization of诊所和可以实现定量体内生化过程。在这样的评论,我们将核成像探针summarize the utilized for the early抗癌治疗的预测和评价模型。99mTc标记的基于类radiopharmaceuticals agents and PET 11C 18F -紫杉醇,异搏定efflux Pumps for Drug will be discussed来成像。此外,有针对性的分子成像探针用于治疗反应评价18F -他莫昔芬一样,89zr曲妥珠单抗introduced in this will also be评论。
关键词: 多药耐药,分子成像、药物外排泵、治疗反应、SPECT、PET。
Current Medicinal Chemistry
Title:Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Volume: 23 Issue: 41
Author(s): Qingqing Meng, Zheng Li, Shaoshun Li
Affiliation:
关键词: 多药耐药,分子成像、药物外排泵、治疗反应、SPECT、PET。
摘要: Multidrug resistance (MDR) describes the resistance of tumor cells to chemotherapy and has been ascribed to the overexpression of drug efflux pumps. Molecular imaging of drug efflux pumps is helpful to identify the patients who may be resistant to the chemotherapy and thus will avoid the unnecessary treatment and increase the therapeutic effectiveness. Imaging probes targeting drug efflux pumps can non-invasively evaluate the Pgp function and play an important role in identification of MDR, prediction of response, and monitoring MDR modulation. On the other hand, new anticancer agents based on molecular targets such as epidermal growth factor receptor (EGFR) and angiogenic factor receptor may potentially be combined with chemotherapeutic drugs to overcome the MDR. Imaging of molecular targets visualize treatment response of patients at molecular level vividly and help to select right patients for certain targeted anticancer therapy. Among all the imaging modalities, nuclear imaging including positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging has the greatest promise for rapid translation to the clinic and can realize quantitative visualization of biochemical processes in vivo. In this review, we will summarize the nuclear imaging probes utilized for predicting and evaluating the early anticancer therapy response. 99mTc labeled agents and PET based radiopharmaceuticals like 18F-Paclitaxel, 11C-Verapamil for drug efflux pumps imaging will be discussed here. Moreover, molecular imaging probes used for targeted therapy response evaluation like 18F-Tamoxifen, 89Zr-Trastuzumab will also be introduced in this review.
Export Options
About this article
Cite this article as:
Qingqing Meng, Zheng Li, Shaoshun Li , Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response, Current Medicinal Chemistry 2016; 23 (41) . https://dx.doi.org/10.2174/0929867323666161101100417
DOI https://dx.doi.org/10.2174/0929867323666161101100417 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Autophagy: A Major Target of Cadmium Nephrotoxicity
Current Chemical Biology Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Pharmacokinetics of Polymeric Micelles for Cancer Treatment
Current Drug Metabolism Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Development and Clinical Application of Tumor-derived Exosomes in Patients with Cancer
Current Stem Cell Research & Therapy Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Ecto-Nucleotidase Inhibitors: Recent Developments in Drug Discovery
Mini-Reviews in Medicinal Chemistry Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets